{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"semaglutide","title":"semaglutide","body":"## Overview\nEvidence is being populated by Grok web search.","hero":null,"images":[],"style":{},"tags":[],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/semaglutide/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40934115/","title":"Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity","quote":"Oral semaglutide at a dose of 25 mg once daily resulted in a greater mean reduction in body weight than placebo in participants with overweight or obesity. (Funded by Novo Nordisk; OASIS 4 ClinicalTrials.gov number, NCT05564117.).","summary":"71-week RCT: -13.6% weight loss with 25 mg oral sema vs -2.2% placebo; more GI AEs.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:15.855Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"bb8f7bdc39d23ad49888cd19a335fda1e7783ea55f1f59f15ef2164ec8f15a12"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40961952/","title":"Once-weekly semaglutide 7·2 mg in adults with obesity","quote":"Semaglutide 7·2 mg was superior to placebo and 2·4 mg for bodyweight reduction in adults with obesity, while retaining a favourable risk-benefit profile.","summary":"Phase 3 trial of higher-dose semaglutide 7.2 mg for obesity.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:15.855Z","link_status":"ok","quote_status":"verified","prev":"bb8f7bdc39d23ad49888cd19a335fda1e7783ea55f1f59f15ef2164ec8f15a12","hash":"a26d95c594e153fa6cee12b32dce33708be46115da745ec03635be9106edef22"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40550013/","title":"Semaglutide in Adults with Type 1 Diabetes and Obesity","quote":"Once-weekly semaglutide is approved for the management of type 2 diabetes and obesity. The efficacy and safety of semaglutide in adults with type 1 diabetes and obesity are unknown.","summary":"RCT evaluating semaglutide in T1D + obesity.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:15.855Z","link_status":"ok","quote_status":"unverified","prev":"a26d95c594e153fa6cee12b32dce33708be46115da745ec03635be9106edef22","hash":"b8aa6e33c7d6a9587c779a0a3bcbb6fc45fb40ff84f9c8bc40dbd815a581f4fa"},{"id":"s4","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/40620322/","title":"The expanding role of semaglutide: beyond glycemic control","quote":"This review outlines semaglutide's diverse mechanisms of action, including its roles in glucose homeostasis, weight reduction, and cardiovascular protection.","summary":"2025 review on semaglutide's expanding indications (NAFLD, HF, PCOS, etc.).","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:15.855Z","link_status":"ok","quote_status":"verified","prev":"b8aa6e33c7d6a9587c779a0a3bcbb6fc45fb40ff84f9c8bc40dbd815a581f4fa","hash":"5ba89ac1dc2887caeb306538931575a3b58a6acb218e5bc5e91b92d905b63c87"},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07046273","title":"Phase III Clinical Study on the Efficacy and Safety of Semaglutide","quote":"A way for patients with serious diseases or conditions who cannot participate in a clinical trial to gain access to a medical product that has not been approved ...","summary":"New Phase III trial registration for semaglutide (Jul 2025).","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:15.855Z","link_status":"ok","quote_status":"unverified","prev":"5ba89ac1dc2887caeb306538931575a3b58a6acb218e5bc5e91b92d905b63c87","hash":"43aabd42096e8232e61d29385dfa4dc0c096e20ac6d4b33e4fddc8ef1f1f0506"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40458885/","title":"Semaglutide in cardiovascular and kidney disease","quote":"Semaglutide enhances glycemic control , reduces major adverse CV events (MACE), and slows chronic kidney disease (CKD) progression.","summary":"Discusses semaglutide benefits in CV and kidney outcomes.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:40.686Z","link_status":"ok","quote_status":"unverified","prev":"43aabd42096e8232e61d29385dfa4dc0c096e20ac6d4b33e4fddc8ef1f1f0506","hash":"ad426f57cb10fd757fd7f601889f824534ba04baa4b49ef0724a3c5de77c70a5"},{"id":"s7","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07627074","title":"Weight Loss in Adults Using Semaglutide (Real-world Study)","quote":"The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at ...","summary":"Real-world study on semaglutide weight loss, published Jun 2026.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:40.686Z","link_status":"ok","quote_status":"unverified","prev":"ad426f57cb10fd757fd7f601889f824534ba04baa4b49ef0724a3c5de77c70a5","hash":"cd0c8309e785256b92d5506a7127de739c27491051f69213c016d128c32e2c4d"},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40732345/","title":"Weight Loss Effects of Once-Weekly Semaglutide 2.4 mg in ...","quote":"Conclusions: The observed difference in weight loss efficacy between the groups was clinically meaningful. While once-weekly semaglutide at 2.4 mg elicited ...","summary":"Study on weight loss efficacy of semaglutide 2.4 mg.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:40.686Z","link_status":"ok","quote_status":"unverified","prev":"cd0c8309e785256b92d5506a7127de739c27491051f69213c016d128c32e2c4d","hash":"d0fbb127adadc67f08440e7f603c74a9e05cfe7e71528c7eea1cd2bea37d6bfa"},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41433034/","title":"Semaglutide and Hospitalizations in Patients With Obesity ...","quote":"Treatment with once-weekly semaglutide was associated with significant reductions in hospital admissions and overall time spent in hospital, ...","summary":"Exploratory analysis from SELECT trial on hospitalizations.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:40.686Z","link_status":"ok","quote_status":"unverified","prev":"d0fbb127adadc67f08440e7f603c74a9e05cfe7e71528c7eea1cd2bea37d6bfa","hash":"e143dd5e102d49671d4f288083c99778f9b4d7464c7e2535d68ad0aa9288f32a"}],"reviews":[],"extra":{},"has_traversal":false,"register":"standard","status":"published","revisions":2,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T17:00:57.494Z","model":"grok-4.3","role":"writer","action":"draft","payload":{"title":"semaglutide","register":"standard","body":"## Overview\nEvidence is being populated by Grok web search.","claims":[],"sources":[]},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"genesis","hash":"0d5a1dd5bae4172a01dc4af7bbf0cf7590ab9c4a571a59dd01fffddc3b757e5a"},{"seq":1,"id":"k2","ts":"2026-06-29T17:01:16.648Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40934115/","title":"Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity","quote":"Oral semaglutide at a dose of 25 mg once daily resulted in a greater mean reduction in body weight than placebo in participants with overweight or obesity. (Funded by Novo Nordisk; OASIS 4 ClinicalTrials.gov number, NCT05564117.).","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40961952/","title":"Once-weekly semaglutide 7·2 mg in adults with obesity","quote":"Semaglutide 7·2 mg was superior to placebo and 2·4 mg for bodyweight reduction in adults with obesity, while retaining a favourable risk-benefit profile.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40550013/","title":"Semaglutide in Adults with Type 1 Diabetes and Obesity","quote":"Once-weekly semaglutide is approved for the management of type 2 diabetes and obesity. The efficacy and safety of semaglutide in adults with type 1 diabetes and obesity are unknown.","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/40620322/","title":"The expanding role of semaglutide: beyond glycemic control","quote":"This review outlines semaglutide's diverse mechanisms of action, including its roles in glucose homeostasis, weight reduction, and cardiovascular protection.","link_status":"ok","quote_status":"verified"},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07046273","title":"Phase III Clinical Study on the Efficacy and Safety of Semaglutide","quote":"A way for patients with serious diseases or conditions who cannot participate in a clinical trial to gain access to a medical product that has not been approved ...","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"0d5a1dd5bae4172a01dc4af7bbf0cf7590ab9c4a571a59dd01fffddc3b757e5a","hash":"cfbf5a3b4134bace32aa620bb5af70719e7f5688c47464cfd997f1008cbce05d"},{"seq":2,"id":"k3","ts":"2026-06-29T17:01:41.374Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40458885/","title":"Semaglutide in cardiovascular and kidney disease","quote":"Semaglutide enhances glycemic control , reduces major adverse CV events (MACE), and slows chronic kidney disease (CKD) progression.","link_status":"ok","quote_status":"unverified"},{"id":"s7","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07627074","title":"Weight Loss in Adults Using Semaglutide (Real-world Study)","quote":"The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at ...","link_status":"ok","quote_status":"unverified"},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40732345/","title":"Weight Loss Effects of Once-Weekly Semaglutide 2.4 mg in ...","quote":"Conclusions: The observed difference in weight loss efficacy between the groups was clinically meaningful. While once-weekly semaglutide at 2.4 mg elicited ...","link_status":"ok","quote_status":"unverified"},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41433034/","title":"Semaglutide and Hospitalizations in Patients With Obesity ...","quote":"Treatment with once-weekly semaglutide was associated with significant reductions in hospital admissions and overall time spent in hospital, ...","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 2","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"cfbf5a3b4134bace32aa620bb5af70719e7f5688c47464cfd997f1008cbce05d","hash":"e2c9583e9a7e4cea1133a0a25c701e08a92979b51a854413c7ffec2d6f6db4e5"}],"provenance":[{"ts":"2026-06-29T17:00:57.494Z","model":"grok-4.3","action":"populate-init","prompt":"","input":"","response":"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"209726646dd533bddd2b3e1d3e813fd55ce1f7931d5ea0d81514f39b7899c5cf"},{"ts":"2026-06-29T17:01:16.648Z","model":"grok-4.3","action":"sources","prompt":"","input":"semaglutide","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"209726646dd533bddd2b3e1d3e813fd55ce1f7931d5ea0d81514f39b7899c5cf","hash":"0315feba54603f97d4e4bffab619879691e33c89a21d7c3c7818fa018eafa894"},{"ts":"2026-06-29T17:01:41.374Z","model":"grok-4.3","action":"sources","prompt":"","input":"semaglutide","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0315feba54603f97d4e4bffab619879691e33c89a21d7c3c7818fa018eafa894","hash":"3ca2ad3327c72bc35f4feb2c2a123cba6cc5360d57f7bbe9f608722f8474ba5d"},{"ts":"2026-07-17T02:41:42.872Z","model":"owner","action":"voxel_divide","prompt":"","input":"semaglutide","response":"2 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"3ca2ad3327c72bc35f4feb2c2a123cba6cc5360d57f7bbe9f608722f8474ba5d","hash":"ae238610ebda3507bb30f0aea512d0abac704a4273d34b5362c1b6aeb57b64d7"}],"energy":{"passes":4,"tokens_in":0,"tokens_out":0,"tokens_total":0,"cost_usd":0,"models":{"grok-4.3":3,"owner":1},"head":"ae238610ebda3507bb30f0aea512d0abac704a4273d34b5362c1b6aeb57b64d7"},"posted_at":"2026-06-29T17:00:57.494Z","created_at":"2026-06-29T17:00:57.494Z","updated_at":"2026-07-17T02:41:42.872Z","machine":{"shape":"article.machine/v1","slug":"semaglutide","kind":"article","read":{"human":"https://miscsubjects.com/a/semaglutide","json":"https://miscsubjects.com/api/articles/semaglutide","bundle":"https://miscsubjects.com/api/articles/semaglutide/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":0,"sources":9,"contributions":3,"revisions":2,"objections_url":"https://miscsubjects.com/api/articles/semaglutide/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=semaglutide","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semaglutide\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semaglutide\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/semaglutide/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"semaglutide\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/semaglutide | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/semaglutide","json":"/api/articles/semaglutide","markdown":"/api/articles/semaglutide/bundle?format=markdown","skill":"/api/articles/semaglutide/skill","topology":"/api/articles/semaglutide/topology","versions":"/api/articles/semaglutide/revisions","invocations":"/api/articles/semaglutide/invocations"},"editorial_review":null,"editorial_audit":{"slug":"semaglutide","ok":false,"issues":[{"code":"headline_quality","message":"headline is too short to orient a cold reader; name the subject and event: \"semaglutide\"","replacement":"Write a shorter literal headline naming the article subject and its central event or claim."},{"code":"heading_filing_label","message":"section heading “Overview” is a filing label that gives a cold reader no claim","replacement":"Replace “Overview” with the concrete claim, event, or object introduced in that section."},{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"dcd6b7bdb3704e6e308dd7c9e774bd45269f7b4d7d44b04b150e3024d021c061","object":{"object_type":"article-object","identity":{"id":"article:semaglutide","slug":"semaglutide","title":"semaglutide"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/semaglutide","role":"explain","audience":"human"},"skill":{"route":"/api/articles/semaglutide/skill","role":"direct behavior","audience":"model","content":"---\nname: semaglutide\ndescription: Apply the semaglutide article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# semaglutide\n\nThis Skill is the behavioral expression of [the canonical article](/a/semaglutide). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/semaglutide.\n- Read claims and relationships at /api/articles/semaglutide/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nOverview Evidence is being populated by Grok web search.\n\n## Representations\n\n- Human: /a/semaglutide\n- JSON: /api/articles/semaglutide\n- Relationships: /api/articles/semaglutide/topology\n- History: /api/articles/semaglutide/revisions\n"},"json":{"route":"/api/articles/semaglutide","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/semaglutide/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["semaglutide"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/semaglutide/invocations?status=success","failure_events":"/api/articles/semaglutide/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"semaglutide","title":"semaglutide","body":"## Overview\nEvidence is being populated by Grok web search.","hero":null,"images":[],"style":{},"tags":[],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/semaglutide/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40934115/","title":"Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity","quote":"Oral semaglutide at a dose of 25 mg once daily resulted in a greater mean reduction in body weight than placebo in participants with overweight or obesity. (Funded by Novo Nordisk; OASIS 4 ClinicalTrials.gov number, NCT05564117.).","summary":"71-week RCT: -13.6% weight loss with 25 mg oral sema vs -2.2% placebo; more GI AEs.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:15.855Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"bb8f7bdc39d23ad49888cd19a335fda1e7783ea55f1f59f15ef2164ec8f15a12"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40961952/","title":"Once-weekly semaglutide 7·2 mg in adults with obesity","quote":"Semaglutide 7·2 mg was superior to placebo and 2·4 mg for bodyweight reduction in adults with obesity, while retaining a favourable risk-benefit profile.","summary":"Phase 3 trial of higher-dose semaglutide 7.2 mg for obesity.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:15.855Z","link_status":"ok","quote_status":"verified","prev":"bb8f7bdc39d23ad49888cd19a335fda1e7783ea55f1f59f15ef2164ec8f15a12","hash":"a26d95c594e153fa6cee12b32dce33708be46115da745ec03635be9106edef22"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40550013/","title":"Semaglutide in Adults with Type 1 Diabetes and Obesity","quote":"Once-weekly semaglutide is approved for the management of type 2 diabetes and obesity. The efficacy and safety of semaglutide in adults with type 1 diabetes and obesity are unknown.","summary":"RCT evaluating semaglutide in T1D + obesity.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:15.855Z","link_status":"ok","quote_status":"unverified","prev":"a26d95c594e153fa6cee12b32dce33708be46115da745ec03635be9106edef22","hash":"b8aa6e33c7d6a9587c779a0a3bcbb6fc45fb40ff84f9c8bc40dbd815a581f4fa"},{"id":"s4","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/40620322/","title":"The expanding role of semaglutide: beyond glycemic control","quote":"This review outlines semaglutide's diverse mechanisms of action, including its roles in glucose homeostasis, weight reduction, and cardiovascular protection.","summary":"2025 review on semaglutide's expanding indications (NAFLD, HF, PCOS, etc.).","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:15.855Z","link_status":"ok","quote_status":"verified","prev":"b8aa6e33c7d6a9587c779a0a3bcbb6fc45fb40ff84f9c8bc40dbd815a581f4fa","hash":"5ba89ac1dc2887caeb306538931575a3b58a6acb218e5bc5e91b92d905b63c87"},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07046273","title":"Phase III Clinical Study on the Efficacy and Safety of Semaglutide","quote":"A way for patients with serious diseases or conditions who cannot participate in a clinical trial to gain access to a medical product that has not been approved ...","summary":"New Phase III trial registration for semaglutide (Jul 2025).","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:15.855Z","link_status":"ok","quote_status":"unverified","prev":"5ba89ac1dc2887caeb306538931575a3b58a6acb218e5bc5e91b92d905b63c87","hash":"43aabd42096e8232e61d29385dfa4dc0c096e20ac6d4b33e4fddc8ef1f1f0506"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40458885/","title":"Semaglutide in cardiovascular and kidney disease","quote":"Semaglutide enhances glycemic control , reduces major adverse CV events (MACE), and slows chronic kidney disease (CKD) progression.","summary":"Discusses semaglutide benefits in CV and kidney outcomes.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:40.686Z","link_status":"ok","quote_status":"unverified","prev":"43aabd42096e8232e61d29385dfa4dc0c096e20ac6d4b33e4fddc8ef1f1f0506","hash":"ad426f57cb10fd757fd7f601889f824534ba04baa4b49ef0724a3c5de77c70a5"},{"id":"s7","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07627074","title":"Weight Loss in Adults Using Semaglutide (Real-world Study)","quote":"The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at ...","summary":"Real-world study on semaglutide weight loss, published Jun 2026.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:40.686Z","link_status":"ok","quote_status":"unverified","prev":"ad426f57cb10fd757fd7f601889f824534ba04baa4b49ef0724a3c5de77c70a5","hash":"cd0c8309e785256b92d5506a7127de739c27491051f69213c016d128c32e2c4d"},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40732345/","title":"Weight Loss Effects of Once-Weekly Semaglutide 2.4 mg in ...","quote":"Conclusions: The observed difference in weight loss efficacy between the groups was clinically meaningful. While once-weekly semaglutide at 2.4 mg elicited ...","summary":"Study on weight loss efficacy of semaglutide 2.4 mg.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:40.686Z","link_status":"ok","quote_status":"unverified","prev":"cd0c8309e785256b92d5506a7127de739c27491051f69213c016d128c32e2c4d","hash":"d0fbb127adadc67f08440e7f603c74a9e05cfe7e71528c7eea1cd2bea37d6bfa"},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41433034/","title":"Semaglutide and Hospitalizations in Patients With Obesity ...","quote":"Treatment with once-weekly semaglutide was associated with significant reductions in hospital admissions and overall time spent in hospital, ...","summary":"Exploratory analysis from SELECT trial on hospitalizations.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:40.686Z","link_status":"ok","quote_status":"unverified","prev":"d0fbb127adadc67f08440e7f603c74a9e05cfe7e71528c7eea1cd2bea37d6bfa","hash":"e143dd5e102d49671d4f288083c99778f9b4d7464c7e2535d68ad0aa9288f32a"}],"reviews":[],"extra":{},"has_traversal":false,"register":"standard","status":"published","revisions":2,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T17:00:57.494Z","model":"grok-4.3","role":"writer","action":"draft","payload":{"title":"semaglutide","register":"standard","body":"## Overview\nEvidence is being populated by Grok web search.","claims":[],"sources":[]},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"genesis","hash":"0d5a1dd5bae4172a01dc4af7bbf0cf7590ab9c4a571a59dd01fffddc3b757e5a"},{"seq":1,"id":"k2","ts":"2026-06-29T17:01:16.648Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40934115/","title":"Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity","quote":"Oral semaglutide at a dose of 25 mg once daily resulted in a greater mean reduction in body weight than placebo in participants with overweight or obesity. (Funded by Novo Nordisk; OASIS 4 ClinicalTrials.gov number, NCT05564117.).","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40961952/","title":"Once-weekly semaglutide 7·2 mg in adults with obesity","quote":"Semaglutide 7·2 mg was superior to placebo and 2·4 mg for bodyweight reduction in adults with obesity, while retaining a favourable risk-benefit profile.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40550013/","title":"Semaglutide in Adults with Type 1 Diabetes and Obesity","quote":"Once-weekly semaglutide is approved for the management of type 2 diabetes and obesity. The efficacy and safety of semaglutide in adults with type 1 diabetes and obesity are unknown.","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/40620322/","title":"The expanding role of semaglutide: beyond glycemic control","quote":"This review outlines semaglutide's diverse mechanisms of action, including its roles in glucose homeostasis, weight reduction, and cardiovascular protection.","link_status":"ok","quote_status":"verified"},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07046273","title":"Phase III Clinical Study on the Efficacy and Safety of Semaglutide","quote":"A way for patients with serious diseases or conditions who cannot participate in a clinical trial to gain access to a medical product that has not been approved ...","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"0d5a1dd5bae4172a01dc4af7bbf0cf7590ab9c4a571a59dd01fffddc3b757e5a","hash":"cfbf5a3b4134bace32aa620bb5af70719e7f5688c47464cfd997f1008cbce05d"},{"seq":2,"id":"k3","ts":"2026-06-29T17:01:41.374Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40458885/","title":"Semaglutide in cardiovascular and kidney disease","quote":"Semaglutide enhances glycemic control , reduces major adverse CV events (MACE), and slows chronic kidney disease (CKD) progression.","link_status":"ok","quote_status":"unverified"},{"id":"s7","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07627074","title":"Weight Loss in Adults Using Semaglutide (Real-world Study)","quote":"The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at ...","link_status":"ok","quote_status":"unverified"},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40732345/","title":"Weight Loss Effects of Once-Weekly Semaglutide 2.4 mg in ...","quote":"Conclusions: The observed difference in weight loss efficacy between the groups was clinically meaningful. While once-weekly semaglutide at 2.4 mg elicited ...","link_status":"ok","quote_status":"unverified"},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41433034/","title":"Semaglutide and Hospitalizations in Patients With Obesity ...","quote":"Treatment with once-weekly semaglutide was associated with significant reductions in hospital admissions and overall time spent in hospital, ...","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 2","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"cfbf5a3b4134bace32aa620bb5af70719e7f5688c47464cfd997f1008cbce05d","hash":"e2c9583e9a7e4cea1133a0a25c701e08a92979b51a854413c7ffec2d6f6db4e5"}],"provenance":[{"ts":"2026-06-29T17:00:57.494Z","model":"grok-4.3","action":"populate-init","prompt":"","input":"","response":"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"209726646dd533bddd2b3e1d3e813fd55ce1f7931d5ea0d81514f39b7899c5cf"},{"ts":"2026-06-29T17:01:16.648Z","model":"grok-4.3","action":"sources","prompt":"","input":"semaglutide","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"209726646dd533bddd2b3e1d3e813fd55ce1f7931d5ea0d81514f39b7899c5cf","hash":"0315feba54603f97d4e4bffab619879691e33c89a21d7c3c7818fa018eafa894"},{"ts":"2026-06-29T17:01:41.374Z","model":"grok-4.3","action":"sources","prompt":"","input":"semaglutide","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0315feba54603f97d4e4bffab619879691e33c89a21d7c3c7818fa018eafa894","hash":"3ca2ad3327c72bc35f4feb2c2a123cba6cc5360d57f7bbe9f608722f8474ba5d"},{"ts":"2026-07-17T02:41:42.872Z","model":"owner","action":"voxel_divide","prompt":"","input":"semaglutide","response":"2 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"3ca2ad3327c72bc35f4feb2c2a123cba6cc5360d57f7bbe9f608722f8474ba5d","hash":"ae238610ebda3507bb30f0aea512d0abac704a4273d34b5362c1b6aeb57b64d7"}],"energy":{"passes":4,"tokens_in":0,"tokens_out":0,"tokens_total":0,"cost_usd":0,"models":{"grok-4.3":3,"owner":1},"head":"ae238610ebda3507bb30f0aea512d0abac704a4273d34b5362c1b6aeb57b64d7"},"posted_at":"2026-06-29T17:00:57.494Z","created_at":"2026-06-29T17:00:57.494Z","updated_at":"2026-07-17T02:41:42.872Z","machine":{"shape":"article.machine/v1","slug":"semaglutide","kind":"article","read":{"human":"https://miscsubjects.com/a/semaglutide","json":"https://miscsubjects.com/api/articles/semaglutide","bundle":"https://miscsubjects.com/api/articles/semaglutide/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":0,"sources":9,"contributions":3,"revisions":2,"objections_url":"https://miscsubjects.com/api/articles/semaglutide/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=semaglutide","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semaglutide\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semaglutide\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/semaglutide/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"semaglutide\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/semaglutide | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/semaglutide","json":"/api/articles/semaglutide","markdown":"/api/articles/semaglutide/bundle?format=markdown","skill":"/api/articles/semaglutide/skill","topology":"/api/articles/semaglutide/topology","versions":"/api/articles/semaglutide/revisions","invocations":"/api/articles/semaglutide/invocations"},"editorial_review":null,"editorial_audit":{"slug":"semaglutide","ok":false,"issues":[{"code":"headline_quality","message":"headline is too short to orient a cold reader; name the subject and event: \"semaglutide\"","replacement":"Write a shorter literal headline naming the article subject and its central event or claim."},{"code":"heading_filing_label","message":"section heading “Overview” is a filing label that gives a cold reader no claim","replacement":"Replace “Overview” with the concrete claim, event, or object introduced in that section."},{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"dcd6b7bdb3704e6e308dd7c9e774bd45269f7b4d7d44b04b150e3024d021c061"}}}